Goldman Sachs analyst David Roman raised the firm’s price target on Beta Bionics (BBNX) to $33 from $26 and keeps a Buy rating on the shares. Beta Bionics’ Q3 results underscore continued strength in the underlying diabetes market as well as the company’s market share gain trajectory, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBNX:
- Beta Bionics price target raised to $23 from $17 at Baird
- Beta Bionics price target raised to $32 from $26 at Piper Sandler
- Beta Bionics Reports Strong Q3 Growth and Raises Guidance
- Beta Bionics reports Q3 EPS (33c), consensus (41c)
- Beta Bionics raises FY25 revenue view to over $96.5M from $88M-$93M prior